李氏大藥廠(00950.HK)上半年純利大增2122.3%至21.55億港元 中期息0.03港元
格隆匯8月26日丨李氏大藥廠(00950.HK)發佈公吿,截至2021年6月30日止6個月,實現收益5.84億港元,同比增長4.9%;毛利3.87億港元,同比增長5.7%;公司擁有人應占溢利21.55億港元,同比增長2122.3%;基本每股盈利366.24港仙;擬派中期息每股0.03港元。
回顧期內,集團旗下集團營銷中心經驗豐富的管理團隊繼續成功引領銷售增長,克服面前挑戰。2021年上半年,集團錄得總收益較去年同期增長4.9%。集團2021年第二季度的總收益較去年同一季度增長6.1%,亦較2021年第一季度增長6.3%。
2021年上半年的增長主要受《尤靖安》®、《菲普利》®、《速樂涓》®及曲前列尼爾注射液的銷售額分別增長94.8%、43.0%、12.8%及142.7%帶動,抵銷了《再寧平》®特許授權終止及《立邁青》®於取得作為那屈肝素鈣注射液的藥品批准文號後需重新安排在醫院上市等負面影響所產生的銷售額跌幅。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.